A European investor was refocusing its investment efforts and considering targeting the oncology cell therapy space. It had a particular interest in tumor infiltrating lymphocytes (TILs) and required expert support to understand the clinical viability of these therapies. Alacrita was commissioned to provide a specialist analysis of successes and failures in TILs clinical trials and to summarize any risks of focusing investments in this space.
Our team of clinical and scientific experts performed a clinical landscape analysis by first generating a curated database on TILs clinical studies. This included all trials parameters (manufacturing method, treatment protocol, patient characteristics) and clinical outcome measures (CR, PR, DoR, PFS, OS) and allowed our oncology expert to make a comparative assessment across the trials. We provided the database and a clinical assessment report to the client for presentation to its investment committee.
As the demands of the pharmaceutical market rise, and new products challenge established principles, it is more important than ever that product strategies meet the needs of providers, payers and patients. Innovations in oncology and immunology are challenging the concept of an approved indication, curative gene and cell therapies are changing payment models, and specialty pharmaceuticals are evolving the supply chain. Alacrita’s commercial consultants bring first-hand experience across a broad range of products and diseases, to help our clients define and execute successful product strategies.